Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial
To our knowledge, this was the first study to report the efficacy and safety of the bispecific HER2-directed ADC TQB2102 in the neoadjuvant setting for HER2-positive breast cancer. TQB2102 showed robust activity and was well-tolerated.
Authors
- Zhenling Li (ORCID: https://orcid.org/0000-0002-6623-1683)
- Li Chen (ORCID: https://orcid.org/0000-0003-2890-4370)
- Yanyan Hu (ORCID: https://orcid.org/0000-0002-1795-4201)
- Xiaohua Zeng (ORCID: https://orcid.org/0000-0001-5810-8055)
- Junjie Li (ORCID: https://orcid.org/0000-0002-0787-4240)
- Guang‐Yu Liu (ORCID: https://orcid.org/0000-0001-5464-4395)
- Wenjuan Zhang (ORCID: https://orcid.org/0000-0001-6972-6449)
- Zhihong Wang (ORCID: https://orcid.org/0000-0003-1667-3536)
- Xiaobo Hu
- Qingyuan Zhang (ORCID: https://orcid.org/0000-0002-7259-1968)
- Jiong Wu (ORCID: https://orcid.org/0000-0002-8103-0505)
- Zhi-Ming Shao (ORCID: https://orcid.org/0009-0001-4577-5358)
Institutions
- Shanghai Medical College of Fudan University (CN)
- Harbin Medical University (CN)
- Fudan University Shanghai Cancer Center (CN)
- China National Pharmaceutical Group Corporation (China) (CN)
- Guizhou Cancer Hospital (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Hunan Cancer Hospital (CN)
- Chongqing Cancer Hospital (CN)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1200/jco-25-01153
- Citations
- 3
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 3.14